Cost-Effectiveness Analysis of Fosfomycin for Treatment of Uncomplicated Urinary Tract Infections in Ontario

Table 3

Results of tornado diagram (decision node).

Variable	Range	Low; EV	High; EV	Spread	Spread^2	Risk; (%)	Cumulative; risk (%)	Variable; index
Probability of developing PN	0.0 to 0.08	88.93	103.46	14.530	211.121	0.553	0.553	0
Probability of hospitalization for PN	0.0 to 0.4	90.56	101.83	11.270	127.013	0.332	0.885	1
Probability of resistance of E. coli to TMP–SMX	0.141 to 0.294	92.64	96.96	4.320	18.662	0.049	0.934	2
Cost of hospitalization for PN	4842.71 to 8993.60	94.41	97.98	3.570	12.745	0.033	0.967	3
Cost of nitrofurantoin	4.68 to 11.12	93.51	96.20	2.690	7.236	0.019	0.986	4
Probability of being infected by E. coli	0.767 to 0.918	95.56	96.86	1.300	1.690	0.004	1	5
Probability of resistance of E. coli to nitrofurantoin	0.0016 to 0.019	96.20	96.20	0.000	0.000	0.000	1	6
Probability of resistance of E. coli to fosfomycin	0.004 to 0.012	96.20	96.20	0.000	0.000	0.000	1	7
Probability of resistance of E. coli to ciprofloxacin	0.191 to 0.245	96.20	58.69	0	0	0.000	1	8
Cost of ciprofloxacin	3.71 to 11.78	96.20	96.20	0.000	0.000	0.000	1	9
Cost of fosfomycin	13.0 to 18.0	96.20	58.69	0	0	0.000	1	10

EV, expected value; PN, pyelonephritis.